- Home
- NCTY vs MAIA Comparison
NCTY vs MAIA Comparison
Compare NCTY & MAIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NCTY
- MAIA
- Stock Information
- Founded
- NCTY 1999
- MAIA 2018
- Country
- NCTY China
- MAIA United States
- Employees
- NCTY N/A
- MAIA N/A
- Industry
- NCTY Business Services
- MAIA Biotechnology: Pharmaceutical Preparations
- Sector
- NCTY Consumer Discretionary
- MAIA Health Care
- Exchange
- NCTY Nasdaq
- MAIA Nasdaq
- Market Cap
- NCTY 75.5M
- MAIA 65.9M
- IPO Year
- NCTY 2004
- MAIA 2022
- Fundamental
- Price
- NCTY $10.95
- MAIA $2.13
- Analyst Decision
- NCTY
- MAIA
- Analyst Count
- NCTY 0
- MAIA 0
- Target Price
- NCTY N/A
- MAIA N/A
- AVG Volume (30 Days)
- NCTY 127.6K
- MAIA 163.9K
- Earning Date
- NCTY 01-01-0001
- MAIA 11-12-2024
- Dividend Yield
- NCTY N/A
- MAIA N/A
- EPS Growth
- NCTY N/A
- MAIA N/A
- EPS
- NCTY 0.84
- MAIA N/A
- Revenue
- NCTY $25,250,543.00
- MAIA N/A
- Revenue This Year
- NCTY N/A
- MAIA N/A
- Revenue Next Year
- NCTY N/A
- MAIA N/A
- P/E Ratio
- NCTY $35.07
- MAIA N/A
- Revenue Growth
- NCTY 65.70
- MAIA N/A
- 52 Week Low
- NCTY $4.03
- MAIA $0.82
- 52 Week High
- NCTY $11.49
- MAIA $5.99
- Technical
- Relative Strength Index (RSI)
- NCTY 73.75
- MAIA 33.62
- Support Level
- NCTY $8.25
- MAIA $2.42
- Resistance Level
- NCTY $8.70
- MAIA $3.48
- Average True Range (ATR)
- NCTY 0.51
- MAIA 0.29
- MACD
- NCTY 0.09
- MAIA -0.06
- Stochastic Oscillator
- NCTY 100.00
- MAIA 1.46
About NCTY The9 Limited American Depository Shares
The9 Ltd operates a cryptocurrency mining business. It provides computing power, or hash rate, to a Bitcoin mining pool and is entitled to receive a fractional share of Bitcoin award from the Bitcoin mining pool in return. The company generates its revenues from customers in Greater China and other areas.
About MAIA MAIA Biotechnology Inc.
MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company. The company develops targeted immunotherapies for cancer. The company is an immune-oncology company, focused on the development of first-in-class drugs with novel mechanisms of action that are intended to meaningfully improve and extend the lives of people with cancer. The company's program is THIO, a potential cancer telomere-targeting agent in clinical development for the treatment of telomerase-positive cancer cells.